137 related articles for article (PubMed ID: 11091744)
1. Plasma Nucleosome Levels in Node-Negative Breast Cancer Patients.
Kuroi K; Tanaka C; Toi M
Breast Cancer; 1999 Oct; 6(4):361-364. PubMed ID: 11091744
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of plasma nucleosome levels in cancer patients.
Kuroi K; Tanaka C; Toi M
Int J Oncol; 2001 Jul; 19(1):143-8. PubMed ID: 11408935
[TBL] [Abstract][Full Text] [Related]
3. p53 as an independent prognostic marker in lymph node-negative breast cancer patients.
Silvestrini R; Benini E; Daidone MG; Veneroni S; Boracchi P; Cappelletti V; Di Fronzo G; Veronesi U
J Natl Cancer Inst; 1993 Jun; 85(12):965-70. PubMed ID: 8496982
[TBL] [Abstract][Full Text] [Related]
4. The influence of young age on outcome in early stage breast cancer.
Fowble BL; Schultz DJ; Overmoyer B; Solin LJ; Fox K; Jardines L; Orel S; Glick JH
Int J Radiat Oncol Biol Phys; 1994 Aug; 30(1):23-33. PubMed ID: 8083119
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma.
Gasparini G; Toi M; Gion M; Verderio P; Dittadi R; Hanatani M; Matsubara I; Vinante O; Bonoldi E; Boracchi P; Gatti C; Suzuki H; Tominaga T
J Natl Cancer Inst; 1997 Jan; 89(2):139-47. PubMed ID: 8998183
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer.
Yamashita H; Ogiya A; Shien T; Horimoto Y; Masuda N; Inao T; Osako T; Takahashi M; Endo Y; Hosoda M; Ishida N; Horii R; Yamazaki K; Miyoshi Y; Yasojima H; Tomioka N;
Breast Cancer; 2016 Nov; 23(6):830-843. PubMed ID: 26467036
[TBL] [Abstract][Full Text] [Related]
7. Predictive of 21-gene recurrence score assay in non-estrogen receptor-positive and lymph node-negative breast cancer.
Lu K; Li H; Wu Z; Liu D; Ye H; Xu L; Liu Y
J BUON; 2018; 23(5):1297-1301. PubMed ID: 30570850
[TBL] [Abstract][Full Text] [Related]
8. The prognostic role of interleukin-8 (IL-8) and matrix metalloproteinases -2 and -9 in lymph node-negative untreated breast cancer patients.
Milovanovic J; Todorovic-Rakovic N; Abu Rabi Z
J BUON; 2013; 18(4):866-73. PubMed ID: 24344010
[TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of cathepsin D and c-erbB-2 oncoprotein in a subgroup of node-negative breast cancer patients with low histological grade tumors.
Gaci Z; Bouin-Pineau MH; Gaci M; Daban A; Ingrand P; Métayé T
Int J Oncol; 2001 Apr; 18(4):793-800. PubMed ID: 11251176
[TBL] [Abstract][Full Text] [Related]
10. [Clinicopathological features and prognostic factors of breast cancer patients with inguinal lymph node metastases: a report of 17 cases].
Li Q; Xu BH; Zhang P; Li Q; Yuan P; Wang JY; Luo Y; Ma F; Fan Y; Li Q
Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):207-11. PubMed ID: 23880002
[TBL] [Abstract][Full Text] [Related]
11. The prognostic value of lymphatic and blood vessel invasion in operable breast cancer.
Lauria R; Perrone F; Carlomagno C; De Laurentiis M; Morabito A; Gallo C; Varriale E; Pettinato G; Panico L; Petrella G
Cancer; 1995 Nov; 76(10):1772-8. PubMed ID: 8625046
[TBL] [Abstract][Full Text] [Related]
12. Steroid receptor status and its clinicopathological correlation in post-menopausal breast cancer patients of Kumaon region of Uttarakhand.
Shahi KS; Bhandari G; Singh A
J Cancer Res Ther; 2011; 7(1):19-22. PubMed ID: 21546737
[TBL] [Abstract][Full Text] [Related]
13. Shc proteins are strong, independent prognostic markers for both node-negative and node-positive primary breast cancer.
Davol PA; Bagdasaryan R; Elfenbein GJ; Maizel AL; Frackelton AR
Cancer Res; 2003 Oct; 63(20):6772-83. PubMed ID: 14583473
[TBL] [Abstract][Full Text] [Related]
14. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
15. Prognosis of a series of 763 consecutive node-negative invasive breast cancer patients without adjuvant therapy: analysis of clinicopathological prognostic factor.
Saimura M; Fukutomi T; Tsuda H; Sato H; Miyamoto K; Akashi-Tanaka S; Nanasawa T
J Surg Oncol; 1999 Jun; 71(2):101-5. PubMed ID: 10389866
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of DNA ploidy in 653 Japanese women with node-negative breast cancer.
Tsutsui S; Ohno S; Murakami S; Hachitanda Y; Oda S
Int J Clin Oncol; 2001 Aug; 6(4):177-82. PubMed ID: 11706555
[TBL] [Abstract][Full Text] [Related]
17. Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trial.
Jueckstock J; Rack B; Friedl TW; Scholz C; Steidl J; Trapp E; Tesch H; Forstbauer H; Lorenz R; Rezai M; Häberle L; Alunni-Fabbroni M; Schneeweiss A; Beckmann MW; Lichtenegger W; Fasching PA; Pantel K; Janni W;
BMC Cancer; 2016 Jul; 16():401. PubMed ID: 27387743
[TBL] [Abstract][Full Text] [Related]
18. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer.
Paterson MC; Dietrich KD; Danyluk J; Paterson AH; Lees AW; Jamil N; Hanson J; Jenkins H; Krause BE; McBlain WA
Cancer Res; 1991 Jan; 51(2):556-67. PubMed ID: 1670762
[TBL] [Abstract][Full Text] [Related]
19. [Clinicopathological characteristics and prognostic factors of breast cancer with estrogen- and progesterone-receptor negative and HER-2 overexpression].
Fan Y; Guan Y; Zhao WH; Li Q; Xu BH
Zhonghua Zhong Liu Za Zhi; 2008 Dec; 30(12):917-20. PubMed ID: 19173993
[TBL] [Abstract][Full Text] [Related]
20. Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer.
Wiedswang G; Borgen E; Kåresen R; Kvalheim G; Nesland JM; Qvist H; Schlichting E; Sauer T; Janbu J; Harbitz T; Naume B
J Clin Oncol; 2003 Sep; 21(18):3469-78. PubMed ID: 12972522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
